These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 32230938)

  • 1. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
    Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies.
    How JA; Jazaeri AA
    Med; 2024 Jun; 5(6):487-489. PubMed ID: 38878765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Uterine Cervical Cancer.
    Kagabu M; Nagasawa T; Fukagawa D; Tomabechi H; Sato S; Shoji T; Baba T
    Healthcare (Basel); 2019 Sep; 7(3):. PubMed ID: 31533297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for cervical cancer: current standard of care and new perspectives.
    Ketch PW; Zaharias RS; Leath CA
    Expert Opin Pharmacother; 2024 Aug; 25(12):1591-1603. PubMed ID: 39164924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
    Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
    J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer.
    Li Y; Shen F; Tan Q; Chen Y; Gu Y
    Technol Cancer Res Treat; 2023; 22():15330338231208846. PubMed ID: 37908109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosting the abscopal effect with chemoradiotherapy/immunotherapy combination in metastatic cervical cancer: a case report.
    Zhang W; Chen M; Xiang Q; Sun S; Cao H; Xie C; Qiu H
    Immunotherapy; 2023 Oct; 15(15):1239-1247. PubMed ID: 37491886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
    Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
    Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
    Otter SJ; Chatterjee J; Stewart AJ; Michael A
    Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Therapies for Melanoma.
    Buchbinder EI
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
    Ventriglia J; Paciolla I; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Califano D; Losito S; Scognamiglio G; Setola SV; Arenare L; Pignata S; Della Pepa C
    Cancer Treat Rev; 2017 Sep; 59():109-116. PubMed ID: 28800469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving standards and future directions for systemic therapies in cervical cancer.
    Ang DJM; Chan JJ
    J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review.
    Shi M; Zhang Y
    Anticancer Drugs; 2024 Aug; 35(7):644-652. PubMed ID: 38950136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
    Kurnit KC; Reid P; Moroney JW; Fleming GF
    Gynecol Oncol; 2020 Sep; 158(3):531-537. PubMed ID: 32641238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature.
    Veccia A; Kinspergher S; Dipasquale M; Caffo O
    Future Oncol; 2021 Feb; 17(5):597-609. PubMed ID: 33401981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
    Dyer BA; Feng CH; Eskander R; Sharabi AB; Mell LK; McHale M; Mayadev JS
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):396-412. PubMed ID: 32942005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer.
    Feng CH; Mell LK; Sharabi AB; McHale M; Mayadev JS
    Semin Radiat Oncol; 2020 Oct; 30(4):273-280. PubMed ID: 32828383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
    Zou Y; Xu Y; Chen X; Zheng L
    Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.